Asset
Firastotug
Adagene Inc. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04501276 | phase1 | completed | 2020-09-23 | 2024-01-17 | Adagene Inc | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients |
| NCT05277402 | phase1 | completed | 2022-02-09 | 2022-08-01 | Adagene Inc | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors |
| NCT04111445 | phase1 | terminated | 2019-08-29 | 2021-04-27 | Adagene Inc | Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.